Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Research & Development (2020 - 2025)

Arcutis Biotherapeutics has reported Research & Development over the past 6 years, most recently at $20.5 million for Q4 2025.

  • Quarterly results put Research & Development at $20.5 million for Q4 2025, up 41.24% from a year ago — trailing twelve months through Dec 2025 was $77.1 million (up 0.83% YoY), and the annual figure for FY2025 was $77.1 million, up 0.83%.
  • Research & Development for Q4 2025 was $20.5 million at Arcutis Biotherapeutics, up from $19.6 million in the prior quarter.
  • Over the last five years, Research & Development for ARQT hit a ceiling of $52.6 million in Q4 2021 and a floor of $14.5 million in Q4 2024.
  • Median Research & Development over the past 5 years was $24.5 million (2023), compared with a mean of $27.6 million.
  • Biggest five-year swings in Research & Development: soared 92.0% in 2021 and later plummeted 39.1% in 2024.
  • Arcutis Biotherapeutics' Research & Development stood at $52.6 million in 2021, then crashed by 35.54% to $33.9 million in 2022, then decreased by 29.82% to $23.8 million in 2023, then plummeted by 39.1% to $14.5 million in 2024, then skyrocketed by 41.24% to $20.5 million in 2025.
  • The last three reported values for Research & Development were $20.5 million (Q4 2025), $19.6 million (Q3 2025), and $19.5 million (Q2 2025) per Business Quant data.